Dr. McDermott on Immunotherapy-Related AEs in RCC

David F. McDermott, MD
Published: Monday, Apr 24, 2017



David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma (RCC).

Adverse events (AEs) with all checkpoint inhibitors are fairly consistent with one another but greatly differ from chemotherapy and targeted agents, McDermott explains. Common related toxicities include inflammation in body organs where the T cells exist and attack healthy issue. Physicians must thoroughly educate their patients about these immune-related AEs and ensure that they report them so they can be appropriately managed. Many of the side effects, he adds, are reversible.

While grade 3/4 complications are relatively less common at approximately 20% of patients, there are some who can die from toxicities associated with immunotherapy if they are not caught and managed quickly. Additionally, he cautions, early intervention will not necessarily shut off the T-cell immune response.
 


David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma (RCC).

Adverse events (AEs) with all checkpoint inhibitors are fairly consistent with one another but greatly differ from chemotherapy and targeted agents, McDermott explains. Common related toxicities include inflammation in body organs where the T cells exist and attack healthy issue. Physicians must thoroughly educate their patients about these immune-related AEs and ensure that they report them so they can be appropriately managed. Many of the side effects, he adds, are reversible.

While grade 3/4 complications are relatively less common at approximately 20% of patients, there are some who can die from toxicities associated with immunotherapy if they are not caught and managed quickly. Additionally, he cautions, early intervention will not necessarily shut off the T-cell immune response.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x